Celgene bags Otezla FDA approval for oral ulcers in Behcet’s Disease
Otezla FDA approval : US biotech company Celgene has bagged approval from the US Food and Drug Administration (FDA) for Otezla (apremilast) for the treatment of oral ulcers associated with Behcet’s Disease in adults. The approved dosage of the oral, selective inhibitor of phosphodiesterase 4 (PDE4) is 30mg twice daily. According to Celgene, Otezla is […]